The Transparency in Coverage (TiC) rule aimed to make healthcare prices easily comparable, but the reported data may pose many barriers to effective analysis.| Peterson-KFF Health System Tracker
The FDA approved a new use for a drug to reduce the risk of serious heart problems in adults with cardiovascular disease and either obesity or overweight.| U.S. Food and Drug Administration
Health insurers submit rate filings annually to state regulators detailing expectations and rate changes for Affordable Care Act (ACA)-regulated health plans for the coming year. A relatively small, but growing, share of the population is enrolled in these plans (compared to the number in employer plans). However, these filings are generally more detailed and publicly […]| Peterson-KFF Health System Tracker
Drugs solely approved to treat obesity have minimal to no coverage on most ACA Marketplace plans. Wegovy, a semaglutide approved for weight loss, is included in just 1% of Marketplace plans, while Ozempic, which has the same active ingredient but is approved for diabetes treatment and sometimes used off-label for weight loss, is included in 82% of Marketplace plan formularies. Among ACA Marketplace plans with these drugs on formulary, prior authorization is required by most plans. All plans ...| Peterson-KFF Health System Tracker
Prices for semaglutide and tirzepatide drugs are higher in the U.S. than in other countries. The U.S. has by far the highest rates of adults with obesity.| Peterson-KFF Health System Tracker
The U.S. has the lowest life expectancy among comparable countries, but spends twice as much as similar countries on healthcare per person, on average.| Peterson-KFF Health System Tracker
